Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Arriagada, R.
Right arrow Articles by Gutiérrez, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arriagada, R.
Right arrow Articles by Gutiérrez, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:663-665, 2003
© 2003 European Society for Medical Oncology

Editorial

Anthracyclines: is more, better and/or more dangerous?

R. Arriagada and J. Gutiérrez

1Instituto de Radiomedicina, Santiago(IRAM), Américo Vespucio Norte 1314, Vitacura, Santiago; 2Hematology and Medical Oncology Department, Clínica Las Condes, Santiago, Chile *(E-mail: datacenter@gocchi.cl)

The first 10% of the full text of this article appears below.

It may seem a strange principle to enunciate

as the very first requirement in a Hospital that

it should do the sick no harm.

Florence Nightingale, Notes on Hospitals, 1863.

Acute non-lymphocytic leukemia is a rare late-effect of the use of adjuvant cytotoxic drugs in breast cancer patients. However, its importance is related to the extremely poor short-term survival of this drug-induced hematologic disease.

It is widely recognized that there are two different syndromes of chemo-induced acute non-lymphocytic leukemia. The first is related to the use of alkylating agents, and involves a first stage of myelodysplasia [1], with a maximal incidence between 5 and 10 years of follow-up [2]. Its morphology is usually of the M1 or M2 type [1], with frequent deletion of chromosomes 5 and 7 [3]. The . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?